Get all premium features to the best stock analysis tool

Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence

Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM ® , SKINVIVE™ and BOTOX ® Cosmetic The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss The company will also host a series of events and educational activities, including a symposium highlighting its global portfolio approach to treatment with AA Signature™ IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education supporting its expanding global aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Dubai, taking place October 21-23, 2026.

AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community

Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases Through the partnership, AbbVie will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, reflecting approximately 10% of people worldwide affected by autoimmune diseases 1,2 AbbVie Race to Innovate will launch at the 2026 Formula 1 United States Grand Prix in Austin and expand throughout the 2027 season NORTH CHICAGO, Ill., Oct. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team.

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased at Week 24 1 Gene expression analysis showed that ABBV-466 treated Crohn's disease patients experienced intestinal tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes reported at Week 24 1 The results will be presented as a late-breaker at the 2026 Annual United European Gastroenterology Week Congress NORTH CHICAGO, Ill.

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented NORTH CHICAGO, Ill., Oct. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain.